drugset / Trial / NCT06341127
Fluoxetine in KCNC1-related Disorder
Completed
1 enrolled
Holland Bloorview Kids Rehabilitation Hospital
The Hospital for Sick Children · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single patient study of oral powdered fluoxetine to target developmental outcomes in a child with KCNC1-related disorder. This trial will be conducted at Holland Bloorview Kids Rehabilitation Hospital over 32 to 42 weeks, using a quasi experimental ABA phase design (placebo-fluoxetine-placebo) with randomized and blinded active treatment start and stop moments.
Timeline
- Start
- 2024-01-17
- Primary completion
- 2024-11-28
- Completion
- 2024-11-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluoxetine | Small molecule | 5 mg | Oral |